4.6 Article

The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult

Journal

KIDNEY INTERNATIONAL REPORTS
Volume 7, Issue 8, Pages 1878-1886

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ekir.2022.05.024

Keywords

focal segmental glomerulosclerosis; rituximab

Funding

  1. Vifor
  2. GlaxoSmithKline
  3. Otsuka
  4. Roche
  5. Amicus
  6. AstraZeneca
  7. Baxter
  8. BBraun
  9. BD Bard
  10. Fresenius
  11. Menarini
  12. Medtronic
  13. Sanofi Genzyme

Ask authors/readers for more resources

Rituximab (RTX) may be a treatment option for primary focal segmental glomerular sclerosis (FSGS), especially in steroid-dependent patients with 24-hour proteinuria <5 g and those who previously responded to RTX. The optimal long-term management for responders is unclear, with some patients experiencing sustained remission and others requiring RTX retreatment, either preemptively or after rising proteinuria.
Introduction: Primary focal segmental glomerular sclerosis (FSGS) is a rare, likely immune-mediated disease. Rituximab (RTX) may play a role in management, although data in adults are scanty.Methods: We collected cases of RTX-treated primary FSGS within the Italian Society of Nephrology Immunopathology Working Group and explored response rate (24-hour proteinuria <3.5 g and <50% compared with baseline, stable estimated glomerular filtration rate).Results: A total of 31 patients were followed for at least 12 months; further follow-up (median 17 months, interquartile range [IQR] 15-33.5) was available for 11. At first RTX administration, median creatinine and 24 -hour proteinuria were 1.17 mg/dl (IQR 0.83-1.62) and 5.2 g (IQR 3.3-8.81), respectively. Response rate at 3, 6, and 12 months was 39%, 52%, and 42%, respectively. In the first 12 months, creatinine level remained stable whereas proteinuria and serum albumin level improved, with an increase in the proportion of patients tapering other immunosuppressants. There were 6 patients who were retreated with RTX within 12 months, either for proteinuria increase or refractory disease; only the 2 responders to the first RTX course experienced a further response. At univariate analysis, 6-month response was more frequent in steroid-dependent patients (odds ratio [OR] 7.7 [95% CI 1.16-52.17]) and those with proteinuria <5 g/24 h (OR 8.25 [1.45-46.86]). During long-term follow-up, 4 of 5 responders at 12 months maintained a sustained response, either without further immuno-suppression (2 of 4) or with pre-emptive RTX (2 of 4); 1 relapsed and responded to RTX retreatment.Conclusion: RTX may be an option in primary FSGS, especially in steroid-dependent patients, with 24 -hour proteinuria <5 g and previously responders to RTX. Optimal long-term management for re-sponders is unclear, with some patients experiencing sustained remission and others requiring RTX retreatment, either preemptive or after rising proteinuria.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available